Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.
Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
1997
Size (employees)
127 (est)
Cytokinetics was founded in 1997 and is headquartered in South San Francisco, US

Key People/Management at Cytokinetics

Robert Blum

Robert Blum

President and Chief Executive Officer
Daniel Casper

Daniel Casper

VP, Information Technology
Bonnie Charpentier

Bonnie Charpentier

SVP, Regulatory Affairs and Compliance
Bettina Cockroft

Bettina Cockroft

VP, Clinical Research, Neurology
David Cragg

David Cragg

SVP, Human Resources
Ching Jaw

Ching Jaw

SVP, Chief Financial Officer
Scott Jordan

Scott Jordan

VP, New Product Planning and Commercial Development
Fady Malik

Fady Malik

EVP, Research and Development
J.D Caryn G. McDowell

J.D Caryn G. McDowell

General Counsel, Chief Compliance Officer and Secretary
Bradley Morgan

Bradley Morgan

SVP, Research and Non-Clinical Development
Peter Roddy

Peter Roddy

SVP, Chief Accounting Officer
Joel Rothman

Joel Rothman

VP, Development Operations
Elisabeth Schnieders

Elisabeth Schnieders

SVP, Business Development
Whittemore Tingley

Whittemore Tingley

VP, Clinical Research, Cardiology
Diane Weiser

Diane Weiser

VP, Corporate Communications and Investor Relations
Andrew Wolff

Andrew Wolff

SVP, Chief Medical Officer

Cytokinetics Office Locations

Cytokinetics has an office in South San Francisco
South San Francisco, US (HQ)
280 E Grand Ave
Show all (1)

Cytokinetics Financials and Metrics

Cytokinetics Financials

Cytokinetics's revenue was reported to be $106.4 m in FY, 2016
USD

Revenue (Q2, 2017)

3.1 m

Net income (Q2, 2017)

(29.1 m)

EBIT (Q2, 2017)

(25.2 m)

Market capitalization (23-Feb-2018)

424.4 m

Cash (30-Jun-2017)

100.7 m

EV

331 m
Cytokinetics's current market capitalization is $424.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

30.6 m46.9 m28.7 m106.4 m

Revenue growth, %

53%(39%)271%

R&D expense

49.5 m59.9 m

General and administrative expense

15.1 m27.8 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

8 m7.8 m9.4 m4.4 m6.5 m7.9 m8.4 m5.8 m59 m4.2 m3.1 m

R&D expense

12.5 m11.7 m11.4 m9 m12.6 m11.6 m13.5 m9.7 m19.3 m19.3 m19.8 m

General and administrative expense

4.3 m4.5 m4 m4.4 m4.5 m5.3 m6.8 m7.1 m7.2 m8.1 m8.4 m

Operating expense total

16.7 m16.2 m15.4 m13.3 m17.1 m16.8 m20.4 m16.8 m26.6 m27.4 m28.2 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.2 m20.2 m65.1 m66.9 m

Current Assets

79.3 m131.1 m113.1 m158.6 m

PP&E

1.2 m1.6 m1.8 m3.6 m

Total Assets

83.2 m133 m115.2 m170.1 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

13.3 m12.4 m12.9 m22.5 m24.8 m26 m42.3 m27.7 m30.3 m49.4 m100.7 m

Accounts Receivable

24 k

Current Assets

86.1 m80.1 m81.5 m110.8 m107.9 m100.5 m106.1 m96.6 m148.2 m211 m317 m

PP&E

1.5 m1.5 m1.5 m1.6 m1.6 m1.5 m1.8 m1.7 m2 m3.5 m3.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.7 m)(14.6 m)(37.5 m)16.5 m

Accounts Payable

1.7 m(2.2 m)755 k1.7 m

Cash From Operating Activities

(7.7 m)(44.8 m)4.9 m37 m

Purchases of PP&E

(542 k)(1.1 m)(562 k)(1.6 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.7 m)(8.4 m)(6 m)(8.9 m)(10.6 m)(8.8 m)(12.5 m)(11.6 m)31.9 m(25.9 m)

Accounts Payable

1.8 m985 k1.6 m1.4 m1.6 m1.9 m547 k2.8 m668 k3 m
Y, 2017

EV/EBIT

-13.1 x

Financial Leverage

1.9 x
Show all financial metrics

Cytokinetics Market Value History

Cytokinetics's Web-traffic and Trends

Cytokinetics Online and Social Media Presence

Cytokinetics Company Life and Culture

You may also be interested in